Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in Sickle Cell Disease
NCT05031780Phase 3Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of mitapivat in sickle cell disease (SCD) (5 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Percentage of Participants With Hemoglobin Response at 52 weeks, Percentage of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious AEs at 56 weeks and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05031780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031780.